首轨生物治疗

最新新闻

• H.C. Wainwright Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $57
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  UBS Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Barclays Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• Guggenheim Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• Evercore Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Piper Sandler Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $95
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  Analysts Offer Insights on NA Companies: Arcturus Therapeutics (ARCT), EquipmentShare.com, Inc. (EQPT) and First Tracks Biotherapeutics Inc (TRAX)
  TipRanks · 2026/8/20
• 评级变动
  Piper Sandler Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $54
  \u5e02\u573a\u8d44\u8baf · 2026/7/20
• 评级变动
  Analysts Offer Insights on NA Companies: Cerebras Systems, Inc. Class A (CBRS), CitroTech (CITR) and First Tracks Biotherapeutics Inc (TRAX)
  TipRanks · 2026/8/13
• 评级变动
  Wedbush Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• 评级变动
  UBS Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  J.P. Morgan Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $65
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  A Quick Look at Today's Ratings for First Tracks Biotherapeutics(TRAX.US), With a Forecast Between $57 to $95
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Barclays Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $48
  \u5e02\u573a\u8d44\u8baf · 2026/7/21
• 评级变动
  Wells Fargo Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• 评级变动
  Analysts Offer Insights on NA Companies: First Tracks Biotherapeutics Inc (TRAX), BETA Technologies, Inc. Class A (BETA) and Cerebras Systems, Inc. Class A (CBRS)
  TipRanks · 2026/8/13
• 评级变动
  H.C. Wainwright Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $44
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• CCORF Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Wells Fargo Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $55
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• Wedbush Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $70
  \u5e02\u573a\u8d44\u8baf · 2026/9/3

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。